RxDoctor Payments Data

Michael Glowacki, MD

Family Medicine · Skaneateles, NYNPI 1730165457

Payments from drug & device makers

$124in general payments, 2019–2025

Across 7 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$32
  • Boehringer Ingelheim$30
  • Medtronic$20
  • Merck$18
  • Novo Nordisk$12
  • Pfizer$12

What the payments were for

  • Food & beverage$124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$32
Boehringer Ingelheim2$30
Medtronic1$20
Merck1$18
Novo Nordisk1$12
Pfizer1$12

How this compares

$124 in reported general payments places this provider in the 25th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$118,250
Medicare patients
257
Services billed
3,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$73,490
JardianceEmpagliflozin49$70,406
XareltoRivaroxaban52$50,759
TrulicityDulaglutide25$49,278
JanuviaSitagliptin Phosphate35$44,012
RybelsusSemaglutide25$33,751
OzempicSemaglutide13$23,041
MounjaroTirzepatide13$20,378
TradjentaLinagliptin13$18,645
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$9,171
Spiriva RespimatTiotropium Bromide12$6,081
Atorvastatin Calcium433$5,434
Levothyroxine Sodium230$4,326
Colesevelam Hcl17$2,949
SymbicortBudesonide/Formoterol Fumarate13$2,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$30$95,13274 claims
PfizerEliquis$12$73,49069 claims
Novo NordiskRybelsus, Ozempic$12$56,79238 claims
MerckJanuvia$18$44,01235 claims
AstraZenecaSymbicort$32$2,83713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 4,321 family medicine providers in New York.

Other family medicine in Skaneateles

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →